CorTechs Labs
Objective brain segmentation and volumetrics to aid physicians in the evaluation of neurodegenerative diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | Series C | |
| Total Funding | 000k | ||
Related Content
Founded in 2001, CorTechs Labs, Inc. operates at the intersection of neuroscience and medical technology, providing advanced medical imaging software. The company originated from the University of California, San Diego, with its foundational technology developed within the university's research labs. The founders include Michael Weiner, a prominent professor in radiology, biomedical imaging, medicine, psychiatry, and neurology, alongside Anders Dale, an expert in neurosciences and radiology. Their extensive academic and research backgrounds in brain imaging directly shaped the company's focus on quantitative analysis for neurological conditions.
CorTechs Labs targets healthcare providers, specifically radiologists, neurologists, and oncologists, operating within the global medical imaging market. Its business model centers on providing software as a medical device, which is integrated into existing clinical workflows in hundreds of clinics and research centers worldwide. Revenue is generated through the sale and licensing of its software products to these healthcare facilities.
The company's principal offering is NeuroQuant®, a medical device that provides quantitative analysis of MRI brain scans. This software automatically segments and measures the volume of various brain structures, comparing them to a normative database adjusted for age and sex. This automated process provides objective data to help clinicians in the assessment of neurodegenerative diseases like Alzheimer's disease, multiple sclerosis, epilepsy, and traumatic brain injury. A key benefit is its ability to deliver these detailed reports in under 10 minutes, enhancing diagnostic efficiency. NeuroQuant has received FDA 510(k) clearance and a CE mark, signifying its compliance with regulatory standards in the US and Europe. In addition to NeuroQuant, the company offers other specialized tools, including a PET imaging solution for evaluating amyloid plaque density, further aiding in Alzheimer's assessment.
Keywords: medical imaging software, neurodiagnostics, quantitative MRI analysis, neurodegenerative diseases, radiology AI, brain volumetry, Alzheimer's assessment, multiple sclerosis analysis, FDA cleared software, clinical decision support